Study gut microbes with immune therapy in several solid cancers
Part of Cancer, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial looks at how the gut microbiome (the bacteria in your digestive system) relates to outcomes when you take standard immune “checkpoint” cancer medicines. If you’re eligible, they’ll collect stool samples while you receive treatment for certain cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have one of these cancers: lung (NSCLC), melanoma (MM), triple-negative breast cancer (TNBC), or kidney cancer (RCC), in stages I–IV
- Your cancer care plan includes a checkpoint inhibitor (anti–PD-1, anti–PD-L1, or anti–CTLA-4), either alone or with other approved treatments
- You can give informed consent and complete questionnaires in English or Spanish
- You can provide stool samples for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how certain cancer drugs (called immune checkpoint inhibitors) interact with other medicines in the body. It aims to help doctors understand how to safely combine these treatments.
This trial studies how gut bacteria (the microbiome) and the body’s immune signs change over time while you receive PD-1–based immunotherapy for advanced, unresectable non–small cell lung cancer. The goal is to learn which immune and microbial patterns might relate to how well treatment works and how patients respond.
This trial studies whether changes in gut bacteria can help predict how well immunotherapy works for solid cancers. It also tests whether stool (fecal microbiota) from certain immunotherapy-responding people can improve outcomes for others who are not responding well.
This study looks at how your gut bacteria might affect a treatment for lung cancer that combines chemotherapy and immunotherapy before surgery. It aims to see if certain bacteria can help the treatment work better.
This trial tests whether the bacteria in your gut (microbiome) can affect how well immunotherapy works for lung cancer that can be surgically removed. You may receive immunotherapy or chemotherapy before surgery to shrink the tumor.
This study looks at how the bacteria in your gut may affect how well immunotherapy works for solid cancers that have spread or cannot be removed. It focuses on people who have been on certain immunotherapy drugs (PD-1 or PD-L1 inhibitors) for at least 3 months but less than 2 years.
Hear when a new Malignant Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.